Program
serplulimab
Also written as “HLX10”, “Serplulimab + chemotherapy (carboplatin-etoposide)” and “HLX10+chemo”.
Its studies are mostly in Small Cell Lung Carcinoma · Colorectal Neoplasms · Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 2512 open or running | phase 3since May 6, 2019 | Nov 19, 2018 | none ahead |
| Guangzhou FineImmune Biotechnology | 11 open or running | phase 1since Mar 4, 2024 | Mar 4, 2024 | none ahead |
| Henlix | 10 open or running | phase 1since Mar 11, 2018 | Mar 11, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Mar 11, 2018.
- Mar 17, 2021Phase 3 study in Uterine Cervical NeoplasmsFosun Pharma · NCT04806945 · China
- Jul 20, 2021Phase 2 study in Squamous Non-small-cell Lung CancerFosun Pharma · NCT04976647 · 156 enrolled · China
- Jan 22, 2022Phase 2 study in ESCC or Esophageal Adenosquamous CarcinomaFosun Pharma · NCT05221658 · 60 planned · China
- Feb 16, 2022Phase 2 study in Stomach NeoplasmsFosun Pharma · NCT05246982 · 40 enrolled · China
- Apr 25, 2022Phase 3 study in Small Cell Lung CarcinomaFosun Pharma · NCT05353257 · 511 enrolled · United States, Austria, China and more
- Apr 26, 2022Phase 2 study in Small Cell Lung CarcinomaFosun Pharma · NCT05354700 · 20 enrolled · China
- May 23, 2022Phase 1 study in Adult Solid TumorFosun Pharma · NCT05400265 · 9 enrolled · China
- Jun 29, 2022Phase 1 study in Solid Tumor, AdultFosun Pharma · NCT05442996 · 30 planned
- Jul 6, 2022Phase 1 study in Advanced or Metastatic Solid TumorsFosun Pharma · NCT05483530 · 20 enrolled · Australia
- Jul 11, 2022Phase 2 study in Extensive Stage Small Cell Lung CancerFosun Pharma · NCT05468489 · 200 enrolled · United States
- Oct 14, 2022Phase 2 study in Colorectal Cancer MetastaticFosun Pharma · NCT05584137 · 2 enrolled · China
- Nov 15, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungFosun Pharma · NCT05641493 · 49 planned · China
- Mar 4, 2024Guangzhou FineImmune Biotechnology's first study: phase 1 study in Drug-Related Side Effects and Adverse ReactionsNew to Guangzhou FineImmune BiotechnologyGuangzhou FineImmune Biotechnology · NCT06302062 · 23 planned · China
- Jan 22, 2025Phase 2 study in SCLC, Extensive StageFosun Pharma · NCT06812260 · 26 enrolled · Japan
TargetBeta
“A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06812260SCLC, Extensive Stage · Japan | 2 | Active, not recruiting | Fosun Pharma | Oct 22, 2026 | 26 |
| NCT06302062Drug-Related Side Effects and Adverse Reactions · China | 1 | Recruiting | Guangzhou FineImmune Biotechnology | Dec 30, 2025 | 23 |
| NCT05641493Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Fosun Pharma | Mar 4, 2025 | 49 |
| NCT05584137Colorectal Cancer Metastatic · China | 2 | Terminated | Fosun Pharma | Dec 31, 2023 | 2 |
| NCT05468489Extensive Stage Small Cell Lung Cancer · United States | 2 | Active, not recruiting | Fosun Pharma | Feb 28, 2026 | 200 |
| NCT05483530Advanced or Metastatic Solid Tumors · Australia | 1 | Active, not recruiting | Fosun Pharma | Dec 2024 | 20 |
| NCT05442996Solid Tumor, Adult | 1 | Not yet recruiting | Fosun Pharma | Apr 22, 2024 | 30 |
| NCT05400265Adult Solid Tumor · China | 1 | Completed | Fosun Pharma | Aug 31, 2023 | 9 |
| NCT05354700Small Cell Lung Carcinoma · China | 2 | UNKNOWN | Fosun Pharma | Mar 29, 2024 | 20 |
| NCT05353257Small Cell Lung Carcinoma · United States, Austria, China and more | 3 | Active, not recruiting | Fosun Pharma | Jun 30, 2026 | 511 |
| NCT05246982Stomach Neoplasms · China | 2 | UNKNOWN | Fosun Pharma | Dec 20, 2023 | 40 |
| NCT05221658ESCC or Esophageal Adenosquamous Carcinoma · China | 2 | Recruiting | Fosun Pharma | Jun 30, 2024 | 60 |
| NCT04976647Squamous Non-small-cell Lung Cancer · China | 2 | UNKNOWN | Fosun Pharma | Jan 30, 2023 | 156 |
| NCT04806945Uterine Cervical Neoplasms · China | 3 | Withdrawn | Fosun Pharma | Feb 15, 2024 | 0 |
| NCT04547166Colorectal Neoplasms · China, Japan | 3 | Recruiting | Fosun Pharma | Sep 24, 2025 | 568 |
| NCT04465734Carcinoma, Hepatocellular · China | 3 | Withdrawn | Fosun Pharma | Oct 15, 2023 | 0 |
| NCT04301739Triple Negative Breast Neoplasms | 3 | Not yet recruiting | Fosun Pharma | Sep 7, 2022 | 522 |
| NCT04150575Uterine Cervical Neoplasms · China | 2 | UNKNOWN | Fosun Pharma | Jun 15, 2022 | 21 |
| NCT04139135Stomach Neoplasms · China | 3 | UNKNOWN | Fosun Pharma | Oct 2023 | 642 |
| NCT04063163Small Cell Lung Carcinoma · Georgia, Poland, Russia and more | 3 | Completed | Fosun Pharma | May 7, 2024 | 585 |
| NCT04033354Neoplasm Metastasis · United States, China, Georgia and more | 3 | Active, not recruiting | Fosun Pharma | Dec 30, 2023 | 537 |
| NCT03973112Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Fosun Pharma | Jun 15, 2022 | 123 |
| NCT03958890Esophageal Squamous Cell Carcinoma · China | 3 | UNKNOWN | Fosun Pharma | Apr 30, 2023 | 489 |
| NCT03952403Carcinoma · China | 3 | Active, not recruiting | Fosun Pharma | Oct 1, 2023 | 643 |
| NCT03941574MSI-H Solid Malignant Tumor · China | 2 | Recruiting | Fosun Pharma | May 30, 2024 | 108 |
| NCT03757936Solid Tumor · China | 1 | UNKNOWN | Fosun Pharma | Sep 27, 2019 | 30 |
| NCT03468751Neoplasm Metastasis · Taiwan | 1 | UNKNOWN | Henlix | Jun 30, 2020 | 30 |
How it is read
Names in the registry
- “HLX10”, 15 entries
- “Serplulimab + chemotherapy (carboplatin-etoposide)”, 1 entry
- “HLX10+chemo”, 1 entry
- “Serplulimab Injection”, 1 entry
- “HLX60 combined with HLX10”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 4 studies
- Colorectal Neoplasms, 2 studies
- Neoplasm Metastasis, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Stomach Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.